All In Biotech

Drug Trial Radar · NCT07761286

Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma

Phase Ib/II Study to Evaluate the Safety, Tolerability and Efficacy of Combination Therapy With SYS6090 Injection in Participants With Hepatocellular Carcinoma

Last checked: Nov 19, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 288 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

288

Planned (sponsor's estimate)

Start

Sep 30, 2026

Primary completion

Sep 30, 2029

Study completion Sep 30, 2031

Sponsor

Sponsor type
Industry
First posted
Aug 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multicenter Phase Ib/II clinical study designed to evaluate the safety, tolerability, and efficacy of combination therapy with SYS6090 Injection in participants with hepatocellular carcinoma (HCC).

Conditions

  • HCC - Hepatocellular Carcinoma

Interventions

  • SYS6090 Injection + Bevacizumab InjectionDrug

    SYS6090 in Combination with Bevacizumab 15mg/kg

  • SYS6090 Injection +SYS6043 Injection +Bevacizumab InjectionDrug

    SYS6090 in Combination with SYS6043 and Bevacizumab 15mg/kg

  • Bevacizumab Injection + Sintilimab InjectionDrug

    Bevacizumab 15mg/kg in Combination with Sintilimab 200mg, intravenous infusion, every 3 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to 2 years.
  2. Overall response rate (ORR)Time frame: Up to 2 years.
  3. DLT;RP2D and MTDTime frame: Up to 2 years.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Harbin medical university Cancer Hospital

    Harbin, Heilongjiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.